

# Elizabeth Jane Phillips

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6043573/publications.pdf>

Version: 2024-02-01

231  
papers

17,801  
citations

22099

59  
h-index

16127

124  
g-index

241  
all docs

241  
docs citations

241  
times ranked

19127  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immediate and Delayed Hypersensitivity Reactions to Beta-Lactam Antibiotics. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 449-462.	2.9	9
2	Janssen COVID-19 vaccine tolerated in 10 patients with confirmed polyethylene glycol allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 859-862.	2.0	11
3	SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. <i>Cell</i> , 2022, 185, 847-859.e11.	13.5	590
4	Low-risk penicillin allergy delabeling through a direct oral challenge in immunocompromised and/or multiple drug allergy labeled patients in a critical care setting. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1660-1663.e2.	2.0	13
5	Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. <i>Nature Nanotechnology</i> , 2022, 17, 337-346.	15.6	74
6	Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors. <i>Communications Biology</i> , 2022, 5, 133.	2.0	3
7	Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1155-1167.e5.	2.0	52
8	Single-cell immunopathology of systemic contact allergy associated with corticosteroids. <i>Journal of Dermatological Science</i> , 2022, 105, 137-140.	1.0	1
9	HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure. <i>Pharmacogenomics Journal</i> , 2022, 22, 124-129.	0.9	5
10	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis—Coordinating Research Priorities to Move the Field Forward. <i>JAMA Dermatology</i> , 2022, 158, 607.	2.0	8
11	<i>ABO</i> O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. <i>Blood</i> , 2022, 140, 274-284.	0.6	9
12	Drug Hypersensitivity: A Glass Half Full. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, xiii-xiv.	0.7	0
13	Recognizing Drug Hypersensitivity in Pigmented Skin. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 219-238.	0.7	6
14	COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA. <i>Lancet Infectious Diseases</i> , The, 2022, , .	4.6	2
15	Addressing beta-lactam allergy: A time for action. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1091-1093.	2.7	3
16	What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 40-51.	0.5	14
17	Rapid progress in our understanding of COVID-19 vaccine allergy: A cause for optimism, not hesitancy. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 12-16.	1.5	11
18	Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	2.0	3

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 4137-4146.	2.5	7
20	Adverse Events and Safety of SARS-CoV-2 Vaccines: What's New and What's Next. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2254-2266.	2.0	4
21	A case of coronavirus disease 2019 messenger RNA vaccine tolerance and immune response despite presence of anti-polyethylene glycol antibodies. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 246-248.	0.5	3
22	Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement. <i>World Allergy Organization Journal</i> , 2022, 15, 100640.	1.6	18
23	IFN- $\gamma$ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2920-2928.e5.	0.3	6
24	Retrospective stratification of cephalosporin allergy label risk using validated penicillin allergy frameworks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2472-2475.e1.	2.0	6
25	Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B. <i>Circulation Research</i> , 2022, 131, 258-276.	2.0	8
26	The Penicillin Allergy Delabeling Program: A Multicenter Whole-of-Hospital Health Services Intervention and Comparative Effectiveness Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 487-496.	2.9	74
27	Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury. <i>Hepatology</i> , 2021, 73, 268-281.	3.6	43
28	Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A*32:01 "positive" vancomycin-induced DRESS sharing an HLA class II haplotype. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 403-405.	1.5	26
29	Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 126-131.	2.2	6
30	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLA-B</i> Genotypes and Phenytoin Dosing: 2020 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 302-309.	2.3	102
31	Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 819-829.e2.	2.0	60
32	Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1731-1733.e3.	2.0	100
33	Testing Strategies and Predictors for Evaluating Immediate and Delayed Reactions to Cephalosporins. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 435-444.e13.	2.0	20
34	Beta-lactam-induced immediate hypersensitivity reactions: A genome-wide association study of a deeply phenotyped cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1830-1837.e15.	1.5	26
35	HLA-B*35:01 and Green Tea-Induced Liver Injury. <i>Hepatology</i> , 2021, 73, 2484-2493.	3.6	53
36	Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. <i>Cell Reports Medicine</i> , 2021, 2, 100204.	3.3	437

#	ARTICLE	IF	CITATIONS
37	Maintaining Safety with SARS-CoV-2 Vaccines. <i>New England Journal of Medicine</i> , 2021, 384, 643-649.	13.9	330
38	Safety, Efficacy, and Effectiveness of Delabeling in Patients with Multiple Drug Allergy Labels. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 922-928.	2.0	11
39	Skin Testing for Penicillin Allergy: a Review of the Literature. <i>Current Allergy and Asthma Reports</i> , 2021, 21, 21.	2.4	9
40	DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 1421-1430.	2.2	10
41	The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2556-2561.	2.0	4
42	mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1423-1437.	2.0	351
43	Reply to "PEG skin testing for COVID-19 allergy". <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1765-1766.	2.0	3
44	Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions. <i>Frontiers in Genetics</i> , 2021, 12, 641905.	1.1	11
45	Role of pharmacogenomics in T-cell hypersensitivity drug reactions. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 327-334.	1.1	3
46	The Role of In Vivo and Ex Vivo Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic Drug Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2010-2015.e4.	2.0	26
47	Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. <i>Liver International</i> , 2021, 41, 1884-1893.	1.9	17
48	Reply to "How important is the second dose of the COVID-19 mRNA vaccine?". <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2537-2539.	2.0	0
49	Visual Genomics Analysis Studio as a Tool to Analyze Multiomic Data. <i>Frontiers in Genetics</i> , 2021, 12, 642012.	1.1	14
50	High-throughput framework for genetic analyses of adverse drug reactions using electronic health records. <i>PLoS Genetics</i> , 2021, 17, e1009593.	1.5	5
51	COVID-19 Vaccination in Patients with Reported Allergic Reactions: Updated Evidence and Suggested Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2135-2138.	2.0	37
52	Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2916-2920.	2.7	59
53	Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 607-615.	2.3	29
54	An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3807-3810.	2.0	6

#	ARTICLE	IF	CITATIONS
55	Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. <i>JAMA Internal Medicine</i> , 2021, 181, 1530.	2.6	84
56	DrugWAS: Drug-wide Association Studies for COVID-19 Drug Repurposing. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1537-1546.	2.3	13
57	Association of KIR Genes and MHC Class I Ligands with Atopic Dermatitis. <i>Journal of Immunology</i> , 2021, 207, 1522-1529.	0.4	10
58	Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US Food and Drug Administration Adverse Event Reporting System. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3208-3211.e1.	2.0	13
59	Allergic Reactions After COVID-19 Vaccination—Putting Risk Into Perspective. <i>JAMA Network Open</i> , 2021, 4, e2122326.	2.8	5
60	Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2968-2982.	2.0	41
61	Considerations for cross-reactivity between vancomycin and other glycopeptides. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3233.	2.0	2
62	The TCR repertoire of Î±-synuclein-specific T cells in Parkinson's disease is surprisingly diverse. <i>Scientific Reports</i> , 2021, 11, 302.	1.6	26
63	mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, , .	2.0	18
64	Antifungal hypersensitivity reactions and cross-reactivity patterns. <i>Current Opinion in Infectious Diseases</i> , 2021, Publish Ahead of Print, 559-572.	1.3	0
65	Reply to "The safety and efficacy of direct oral challenge in trimethoprim-sulfamethoxazole antibiotic allergy". <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3849-3850.	2.0	3
66	Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level. <i>Pathogens and Immunity</i> , 2021, 6, 27-49.	1.4	10
67	Severe COVID-19 Is Associated With an Altered Upper Respiratory Tract Microbiome. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781968.	1.8	27
68	The challenge of de-labeling penicillin allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 273-288.	2.7	136
69	Oral challenge with trimethoprim-sulfamethoxazole in patients with cefsulfa antibiotic allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 757-760.e4.	2.0	37
70	Safety of cephalosporins in penicillin class severe delayed hypersensitivity reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1142-1146.e4.	2.0	22
71	Analysis of Skin-Resident Memory T Cells Following Drug Hypersensitivity Reactions. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1442-1445.e4.	0.3	19
72	Highlights from the 2nd Biennial Stevens Johnson syndrome symposium 2019: SJS/TEN from Science to Translation. <i>Ocular Surface</i> , 2020, 18, 483-486.	2.2	2

#	ARTICLE	IF	CITATIONS
73	Implications of electronic health record transition on drug allergy labels. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 764-766.	2.0	8
74	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, S16-S116.	2.0	107
75	Positioning Drug Allergy Delabeling as a Critical Tool for Precision Medicine, Quality Improvement, and Public Health. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2916-2919.	2.0	5
76	Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2878-2895.e6.	2.0	27
77	Readiness for Penicillin Allergy de-labeling: Perception of Allergy Label (PenPAL) Survey. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB343.	1.5	1
78	A Review of Î²-Lactamâ€™Associated Neutropenia and Implications for Cross-reactivity. <i>Annals of Pharmacotherapy</i> , 2020, 55, 106002802097564.	0.9	10
79	Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccines. <i>Viruses</i> , 2020, 12, 1300.	1.5	3
80	Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. <i>Science</i> , 2020, 370, 89-94.	6.0	1,036
81	Readiness for PENicillin allergy testing: Perception of Allergy Label (PEN-PAL) survey. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3180-3182.e4.	2.0	11
82	Penicillin allergy labels drive perioperative prophylactic antibiotic selection in orthopedic procedures. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3634-3636.e1.	2.0	10
83	Identification and Characterization of CD4 <sup>+</sup> T Cell Epitopes after Shingrix Vaccination. <i>Journal of Virology</i> , 2020, 94, .	1.5	18
84	The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 518-534.e1.	1.5	180
85	New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals. <i>Human Immunology</i> , 2020, 81, 300-304.	1.2	19
86	Delayed hypersensitivity associated with amoxicillinâ€™clavulanate. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2700-2702.	2.7	7
87	Children with reported penicillin allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 558-565.	0.5	42
88	Pharmacogenomic biomarkers in allergy and immunology practice. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 509-512.	1.5	10
89	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	1.1	34
90	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020, 98, 2-12.	1.0	41

#	ARTICLE	IF	CITATIONS
91	Development and Validation of a Penicillin Allergy Clinical Decision Rule. <i>JAMA Internal Medicine</i> , 2020, 180, 745.	2.6	135
92	Risk-stratified Management to Remove Low-Risk Penicillin Allergy Labels in the ICU. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1572-1575.	2.5	44
93	Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macroglobulin allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1416-1419.e3.	2.0	39
94	Î±-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinsonâ€™s disease. <i>Nature Communications</i> , 2020, 11, 1875.	5.8	239
95	An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity. <i>Frontiers in Pharmacology</i> , 2020, 11, 573573.	1.6	32
96	Genome-wide Study Identifies Association between HLA-B*57:01 and Self-Reported Penicillin Allergy. <i>American Journal of Human Genetics</i> , 2020, 107, 612-621.	2.6	34
97	Genome-Wide Association Study Identifies Variation in <i>ABO</i> As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia. <i>Blood</i> , 2020, 136, 38-39.	0.6	1
98	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 463-486.	4.2	42
99	Defining Regional Differences in Drug-Induced Stevensâ€™Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 22-25.	2.3	3
100	Anaphylaxis after vaccination in a pediatric patient: further implicating alpha-gal allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 322-324.e2.	2.0	44
101	Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis. <i>Hepatology International</i> , 2019, 13, 641-648.	1.9	32
102	Identification of drug-specific public TCR driving severe cutaneous adverse reactions. <i>Nature Communications</i> , 2019, 10, 3569.	5.8	83
103	A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 782-789.	1.2	12
104	Reply. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2095-2096.	2.0	0
105	Slow graded reintroduction of oxcarbazepine for delayed maculopapular eruption. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 411-412.	0.5	3
106	Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses. <i>Frontiers in Immunology</i> , 2019, 10, 1568.	2.2	35
107	Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised Hosts. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2151-2153.	2.0	22
108	Immune-mediated adverse reactions to vaccines. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2694-2706.	1.1	129

#	ARTICLE	IF	CITATIONS
109	Cephalosporin Allergy: Current Understanding and Future Challenges. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2105-2114.	2.0	69
110	Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1413-1416.e7.	1.5	19
111	Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1533-1540.e8.	2.0	257
112	High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2163-2169.	1.1	19
113	The Influence of Patient Anxiety and Perception on the Effectiveness of Drug Allergy Testing. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB428.	1.5	1
114	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1028-1036.	2.3	52
115	Widespread Tau-Specific CD4 T Cell Reactivity in the General Population. <i>Journal of Immunology</i> , 2019, 203, 84-92.	0.4	36
116	HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 183-192.	1.5	118
117	Oral Challenge with Trimethoprim-Sulfamethoxazole in Patients with Sulfonamide Antibiotic Allergy Referred to an Outpatient Drug Allergy Clinic. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB209.	1.5	5
118	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Carbonic Anhydrase Inhibitors: Epidemiology, Genetics, and Insights into Mechanisms. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2854-2856.	2.0	0
119	Penicillin Allergy. <i>New England Journal of Medicine</i> , 2019, 381, 2338-2351.	13.9	159
120	Controversies in drug allergy: Testing for delayed reactions. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 66-73.	1.5	144
121	Prevention and Diagnosis of Severe T-Cell-Mediated Adverse Drug Reactions: Are We There Yet?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 228-230.	2.0	3
122	The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1341-1343.e1.	2.0	25
123	Antibiotic allergy. <i>Lancet</i> , 2019, 393, 183-198.	6.3	358
124	Pathways to improved antibiotic allergy and antimicrobial stewardship practice: The validation of a beta-lactam antibiotic allergy assessment tool. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1063-1065.e5.	2.0	65
125	Future Directions and Unmet Research Needs in Cutaneous Adverse Drug Reactions. , 2019, , 275-282.		0
126	Antibiotic Use After Removal of Penicillin Allergy Label. <i>Pediatrics</i> , 2018, 141, .	1.0	44



#	ARTICLE	IF	CITATIONS
127	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 574-581.	2.3	211
128	The Combined Utility of ExÂVivo IFN-Î³ Release Enzyme-Linked ImmunoSpot Assay and InÂVivo SkinÂTesting in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1287-1296.e1.	2.0	47
129	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	2.0	134
130	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 714 adults from Colombo, Sri Lanka. <i>Human Immunology</i> , 2018, 79, 87-88.	1.2	7
131	Antibiotic Allergy in Pediatrics. <i>Pediatrics</i> , 2018, 141, .	1.0	83
132	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 159 individuals from the Worcester region of the Western Cape province of South Africa. <i>Human Immunology</i> , 2018, 79, 143-144.	1.2	7
133	A survey of drug allergy training opportunities in the United States. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 302-304.	2.0	9
134	Immune Mechanisms of Drug Allergy. , 2018, , 27-38.		0
135	Pharmacogenomics of Drug Allergy. , 2018, , 39-51.		0
136	Research Directions in Genetic Predispositions to Stevensâ€Johnson Syndrome / Toxic Epidermal Necrolysis. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 390-394.	2.3	15
137	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 339 adults from Managua, Nicaragua. <i>Human Immunology</i> , 2018, 79, 1-2.	1.2	8
138	The Safety and Efficacy of an Oral Penicillin Challenge Program in Cancer Patients: A Multicenter Pilot Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy306.	0.4	57
139	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 496 adults from San Diego, California, USA. <i>Human Immunology</i> , 2018, 79, 821-822.	1.2	10
140	How antibiotic allergy labels may be harming our most vulnerable patients. <i>Medical Journal of Australia</i> , 2018, 208, 469-470.	0.8	15
141	Urinary Peptides As a Novel Source of T Cell Allergen Epitopes. <i>Frontiers in Immunology</i> , 2018, 9, 886.	2.2	16
142	The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. <i>Journal of Hepatology</i> , 2018, 69, 1317-1325.	1.8	32
143	Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration. <i>Journal of Clinical Investigation</i> , 2018, 128, 2746-2749.	3.9	13
144	NEW STRATEGIES TO PREDICT AND PREVENT SERIOUS IMMUNOLOGICALLY MEDIATED ADVERSE DRUG REACTIONS. <i>Transactions of the American Clinical and Climatological Association</i> , 2018, 129, 74-87.	0.9	5

#	ARTICLE	IF	CITATIONS
145	Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2 <sup>1</sup> 30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. <i>Journal of Virology</i> , 2017, 91, .	1.5	24
146	Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. <i>Clinical Infectious Diseases</i> , 2017, 64, 1198-1203.	2.9	27
147	Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	105
148	Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 547-563.	2.0	106
149	Drug-specific upregulation of CD137 on CD8+ T cells aids in the diagnosis of multiple antibiotic toxic epidermal necrolysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 823-826.	2.0	13
150	T cells from patients with Parkinson's disease recognize $\alpha$ -synuclein peptides. <i>Nature</i> , 2017, 546, 656-661.	13.7	618
151	Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation. <i>Clinical Infectious Diseases</i> , 2017, 65, 166-174.	2.9	106
152	Pharmacogenomics of off-target adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1896-1911.	1.1	48
153	Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 100 Luo infants from the Boro area of Nyanza Province, Kenya. <i>Human Immunology</i> , 2017, 78, 325-326.	1.2	6
154	Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1710-1713.e2.	1.5	61
155	Human CD4 <sup>+</sup> T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity. <i>Journal of Virology</i> , 2017, 91, .	1.5	83
156	Cytomegalovirus (CMV) Epitope-Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects. <i>Journal of Immunology</i> , 2017, 199, 3187-3201.	0.4	55
157	Severe Delayed Drug Reactions. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 785-815.	0.7	27
158	Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. <i>Journal of Virology</i> , 2017, 91, .	1.5	148
159	The 3 Cs of Antibiotic Allergy—Classification, Cross-Reactivity, and Collaboration. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1532-1542.	2.0	60
160	Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. <i>Scientific Reports</i> , 2017, 7, 8653.	1.6	41
161	Persistence of Penicillin Allergy—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1714.	3.8	4
162	Penicillin Allergy Is Not Necessarily Forever. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 82.	3.8	139

#	ARTICLE	IF	CITATIONS
163	Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 816-818.	2.0	25
164	Global Assessment of Dengue Virus-Specific CD4+ T Cell Responses in Dengue-Endemic Areas. <i>Frontiers in Immunology</i> , 2017, 8, 1309.	2.2	77
165	Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses. <i>PLoS ONE</i> , 2017, 12, e0169086.	1.1	60
166	Comparison of HLA allelic imputation programs. <i>PLoS ONE</i> , 2017, 12, e0172444.	1.1	58
167	Genomic testing as a tool to optimise drug therapy. <i>Australian Prescriber</i> , 2017, 40, 101-104.	0.5	12
168	Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw153.	0.4	57
169	Mechanism of isoniazidâ€­induced hepatotoxicity: then and now. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1030-1036.	1.1	140
170	Classifying ADRs â€­ does dose matter?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 10-12.	1.1	27
171	HLA-DRB1 Alleles Are Associated With Different Magnitudes of Dengue Virusâ€­Specific CD4 <sup>+</sup> T-Cell Responses. <i>Journal of Infectious Diseases</i> , 2016, 214, 1117-1124.	1.9	88
172	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016, 375, 1749-1755.	13.9	1,668
173	Identifying genetically driven clinical phenotypes using linear mixed models. <i>Nature Communications</i> , 2016, 7, 11433.	5.8	12
174	Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 561-576.	1.3	15
175	Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses. <i>Journal of Immunology</i> , 2016, 196, 2205-2218.	0.4	55
176	Adding the â€­medicinesâ€­ back into personalized medicine to improve cancer treatment outcomes. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 929-931.	1.1	5
177	Abacavir-Reactive Memory T Cells Are Present in Drug Naïve Individuals. <i>PLoS ONE</i> , 2015, 10, e0117160.	1.1	73
178	Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity. <i>PLoS ONE</i> , 2015, 10, e0124878.	1.1	11
179	Improving the Effectiveness of Penicillin Allergy De-labeling. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 365-374.e1.	2.0	113
180	Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 262-271.e2.	1.5	51

#	ARTICLE	IF	CITATIONS
181	Evolving models of the immunopathogenesis of T <sub>H</sub> 1-mediated drug allergy: The role of host, pathogens, and drug response. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 219-234.	1.5	185
182	Penicillin allergy label persists despite negative testing. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 815-816.	2.0	41
183	Varying penicillin allergy testing practices in the United States: A time for consensus. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 791-793.	2.0	11
184	Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 527-535.	2.9	79
185	The evolving story of human leukocyte antigen and the immunogenetics of peanut allergy. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 471-476.	0.5	12
186	T Cell-Mediated Hypersensitivity Reactions to Drugs. <i>Annual Review of Medicine</i> , 2015, 66, 439-454.	5.0	109
187	The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 182-194.	1.1	123
188	Response to letter regarding article "Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis". <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 931-932.	1.1	1
189	HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity. <i>Aids</i> , 2014, 28, 1891-1901.	1.0	48
190	Genotyping for Severe Drug Hypersensitivity. <i>Current Allergy and Asthma Reports</i> , 2014, 14, 418.	2.4	35
191	Exploring the link between pholcodine exposure and neuromuscular blocking agent anaphylaxis. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 14-23.	1.1	31
192	HLA class I drug-T cell receptor interactions in SJS/TEN. <i>Clinical and Translational Allergy</i> , 2014, 4, P2.	1.4	0
193	Antiviral Drug Allergy. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 645-662.	0.7	10
194	Fever, Rash, and Systemic Symptoms: Understanding the Role of Virus and HLA in Severe Cutaneous Drug Allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 21-33.	2.0	74
195	Associations Between HLA-DRB1*0102, HLA-B*5801, and Hepatotoxicity During Initiation of Nevirapine-Containing Regimens in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, e55-e57.	0.9	51
196	HLA-B*5701 and flucloxacillin associated drug-induced liver disease. <i>Aids</i> , 2013, 27, 491-492.	1.0	13
197	Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to "de-labeling". <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 526-537.	1.3	92
198	HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13492-13497.	3.3	47

#	ARTICLE	IF	CITATIONS
199	Testing for drug hypersensitivity syndromes. <i>Clinical Biochemist Reviews</i> , 2013, 34, 15-38.	3.3	56
200	Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9959-9964.	3.3	354
201	HLA and pharmacogenetics of drug hypersensitivity. <i>Pharmacogenomics</i> , 2012, 13, 1285-1306.	0.6	161
202	The structural basis of HLA-associated drug hypersensitivity syndromes. <i>Immunological Reviews</i> , 2012, 250, 158-166.	2.8	31
203	Individualization of antiretroviral therapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2011, 5, 1.	0.4	16
204	Mapping the Landscape of Host-Pathogen Coevolution: HLA Class I Binding and Its Relationship with Evolutionary Conservation in Human and Viral Proteins. <i>Journal of Virology</i> , 2011, 85, 1310-1321.	1.5	62
205	Pharmacogenetics of drug hypersensitivity. <i>Pharmacogenomics</i> , 2010, 11, 973-987.	0.6	98
206	Successful Translation of Pharmacogenetics into the Clinic. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 1-9.	1.6	101
207	HLA and drug-induced toxicity. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 231-42.	2.8	22
208	HLA-B*5701 Screening for Hypersensitivity to Abacavir. <i>New England Journal of Medicine</i> , 2008, 358, 568-579.	13.9	1,665
209	A review of drug patch testing and implications for HIV clinicians. <i>Aids</i> , 2008, 22, 999-1007.	1.0	45
210	High Sensitivity of Human Leukocyte Antigen B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients. <i>Clinical Infectious Diseases</i> , 2008, 46, 1111-1118.	2.9	384
211	Cytokine profiling in abacavir hypersensitivity patients. <i>Antiviral Therapy</i> , 2008, 13, 281-8.	0.6	9
212	Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008, 13, 1019-28.	0.6	7
213	Cytokine Profiling in Abacavir Hypersensitivity Patients. <i>Antiviral Therapy</i> , 2008, 13, 281-288.	0.6	22
214	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008, 13, 1019-1028.	0.6	29
215	Abacavir Hypersensitivity. , 2007, , 95-104.		1
216	Drug hypersensitivity in HIV. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2007, 7, 324-330.	1.1	91

#	ARTICLE	IF	CITATIONS
217	Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. <i>Aids</i> , 2007, 21, 1233-1244.	1.0	48
218	Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naïve HIV-positive patients. <i>Aids</i> , 2007, 21, 1561-1568.	1.0	36
219	External quality assessment of HLA-B*5701 reporting: an international multicentre survey. <i>Antiviral Therapy</i> , 2007, 12, 1027-32.	0.6	17
220	External Quality Assessment of <i>HLA-B*5701</i> Reporting: An International Multicentre Survey. <i>Antiviral Therapy</i> , 2007, 12, 1027-1032.	0.6	40
221	A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 353-357.	0.7	47
222	Efavirenz and CYP2B6 Polymorphism: Implications for Drug Toxicity and Resistance. <i>Clinical Infectious Diseases</i> , 2006, 42, 408-410.	2.9	42
223	Clinical and immunogenetic correlates of abacavir hypersensitivity. <i>Aids</i> , 2005, 19, 979-981.	1.0	169
224	Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. <i>Aids</i> , 2005, 19, 97-99.	1.0	282
225	Clindamycin skin testing has limited diagnostic potential. <i>Contact Dermatitis</i> , 2005, 53, 335-338.	0.8	23
226	Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 1-7.	0.8	70
227	Natural health productâ€™HIV drug interactions: a systematic review. <i>International Journal of STD and AIDS</i> , 2005, 16, 181-186.	0.5	48
228	Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. <i>Pharmacogenomics</i> , 2004, 5, 643-655.	0.6	33
229	Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4180-4185.	3.3	451
230	Efavirenz-Induced Skin Eruption and Successful Desensitization. <i>Annals of Pharmacotherapy</i> , 2002, 36, 430-432.	0.9	38
231	Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. <i>Aids</i> , 2002, 16, 2223-2225.	1.0	129